title: [Influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B].
abstract: OBJECTIVE
  To explore the influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B (CHB).
  
  
  METHODS
  10 mg adefovir dipivoxil (Zhengda Tianjing Pharmaceutical Company) was used for CHB patients with positive HBV DNA (HBV DNA > or = 1 x 10(4) copies/ml), ALT > 2 x upper limit of normal value (ULN) and positive human leucocyte antigen (HLA)-A2, orally, once a day for 3 months. Real time fluorescent quantitative PCR was used to determine HBV DNA and flowcytometer was used to determine HBV specific CTL.
  
  
  RESULTS
  After treatment with adefovir dipivoxil for 3 months, HBV specific CTL (0.52 +/- 0.11)% was higher than that before treatment (0.34 +/- 0.14)%, t = 6.78 P < 0.01, HBV DNA of 28 cases turned to negative (<1 x 10(3) copies/ml) (62.22%). HBV DNA of 17 cases failed to turn negative 3 months after treatment, but their HBV DNA level was lower [(4. 18 +/- 0.4) log 10 copies/ml] than that before treatment [(6.23 +/- 0.73) log 10 copies/ml], t = 9.99, P < 0.01.
  
  
  CONCLUSIONS
  Adefovir dipivoxil can improve HBV specific cellular immunity in patients CHB.
authors.affiliation: Department of Infectious Diseases, Yixing People's Hospital 214200, China.
authors.forename: Yu-lin
authors.initials: YL
authors.lastname: Zhou
authors.forename: Xue-cai
authors.initials: XC
authors.lastname: Wang
authors.forename: Yin-tao
authors.initials: YT
authors.lastname: Wu
authors.forename: Yong-fei
authors.initials: YF
authors.lastname: Tan
authors.forename: Yan-ping
authors.initials: YP
authors.lastname: Zhao
authors.forename: Jun-ming
authors.initials: JM
authors.lastname: Tang
authors.forename: Jian-qiang
authors.initials: JQ
authors.lastname: Pan
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage*; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects* / Q000276:immunology; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D000225:Adenine; C106812:adefovir dipivoxil